CARLSBAD, Calif. -- (BUSINESS WIRE) -- Applied Spectral Imaging (ASI, www.spectral-imaging.com) announced today the launch of GenASIs Go-Path – computer aided membrane and nuclear immunohistochemistry imaging and analysis platform.
GenASIs Go-Path introduces major enhancements to ASI’s newly introduced GenASIs 7.2 imaging and analysis platforms, positioning ASI as a leader in computer aided pathology immunohistochemistry analysis for cancer and other IHC applications. Go-Path includes unparalleled accuracy and efficiency in computer aided immunohistochemistry imaging and analysis.
“Go-Path computerized IHC scoring-aid, our flagship offering, coupled with our advanced FISH imaging and analysis solutions, further establish ASI as a leader in automated and interactive pathology and cytogenetic imaging and analysis solutions. We are excited to add Quantitative IHC pathology imaging and analysis, along with other important enhancements, to our leading platform – GenASIs 7.2. This new platform is in line with our strategy to offer clinicians and researchers the most advanced, efficient and accurate instruments supporting advancements in computer-aided analysis for personalized medicine, companion diagnostics, cancer research, diagnostic and other pathology and cytogenetic applications. “ said Limor Shiposh, CEO of Applied Spectral Imaging. Limor added: “Combining IHC, FISH and cytogenetic imaging and analysis adds real value to our customers. We are committed to making patient care better and more affordable through advanced biomedical imaging.”
GenASIs Go-Path introduces, for the first time, ASI’s innovative “Point-of-View” pathology imaging and analysis. The Go-Path instrument allows users to adopt a “Point-Acquire-Score” workflow. Users simply target a cancer region under the microscope, hit a button to capture an image and automatically receive a computer generated scoring map to aid in scoring. Go-Path makes IHC scoring quick, accurate and repeatable, enhancing the quality and consistency of the results. Go-Path is not FDA cleared for clinical use and is to be used for research only.
Applied Spectral Imaging (ASI) makes patient care better through advanced biomedical imaging.
GenASIs by ASI is FDA cleared for FISH clinical applications such as UroVysion, HER2/neu, CEP XY and Karyotyping. ASI complies with major regulatory requirements and international quality standards.
ASI has been one of the industry's leading microscopy imaging solution provider since 1993, with over 30 registered patents in the US, Europe and Japan, and over 2,500 systems deployed worldwide. With worldwide offices in the US, Europe and Asia, ASI has built a global network of over 50 distributors.
# # #